Trivium Point Advisory’s Gilead Sciences GILD Stock Holding History

Trivium Point Advisory’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$898K	Buy	7,111 +774	+12%	+$102K	0.08%	195
2026 Q1	$883K	Sell	6,337 -1,092	-15%	-$153K	0.16%	137
2025 Q4	$912K	Buy	7,429 +104	+1%	+$12.6K	0.09%	187
2025 Q3	$813K	Buy	7,325 +83	+1%	+$9.43K	0.08%	199
2025 Q2	$803K	Buy	7,242 +5,406	+294%	+$575K	0.09%	204
2025 Q1	$206K	Buy	+1,836	New	+$189K	0.03%	326
2024 Q3	–	Sell	-3,648	Closed	-$250K	–	336
2024 Q2	$250K	Buy	+3,648	New	+$243K	0.04%	271
2024 Q1	–	Sell	-24,771	Closed	-$2.01M	–	227
2023 Q4	$2.01M	Buy	24,771 +533	+2%	+$41.5K	0.49%	62
2023 Q3	$1.78M	Buy	24,238 +1,052	+5%	+$80.9K	0.49%	68
2023 Q2	$1.79M	Buy	23,186 +1,514	+7%	+$121K	0.48%	70
2023 Q1	$1.8M	Buy	21,672 +551	+3%	+$45.6K	0.49%	68
2022 Q4	$1.86M	Buy	21,121 +2,876	+16%	+$228K	0.54%	65
2022 Q3	$1.19M	Buy	18,245 +7,624	+72%	+$481K	0.37%	89
2022 Q2	$666K	Buy	+10,621	New	+$658K	0.2%	131

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Trivium Point Advisory's GILD Position: Q2 2026 in Review

Trivium Point Advisory increased its Gilead Sciences (GILD) stake by 12% in Q2 2026, buying an estimated $102K and bringing the position to 7,111 shares worth $898K. The position accounts for 0.08% of the portfolio, ranked #195.

Trivium Point Advisory first reported a position in GILD in Q2 2022 and has held it in 14 quarters since. The position peaked at $2.01M in Q4 2023. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Trivium Point Advisory held 7,111 shares of Gilead Sciences worth $898K as of Q2 2026.
Trivium Point Advisory bought 774 Gilead Sciences shares in Q2 2026, an estimated $102K.
Gilead Sciences made up 0.08% of Trivium Point Advisory's portfolio in Q2 2026, its #195 holding.
Trivium Point Advisory first reported a position in Gilead Sciences in Q2 2022 and has held it in 14 quarters since.
Trivium Point Advisory's Gilead Sciences position peaked at $2.01M in Q4 2023.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Trivium Point Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.